DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Treatment Algorithms: Claims Data Analysis – Neuropsychiatric Therapies in Alzheimer’s Disease (US) | 2024
In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…
Neuropathic Pain – Current Treatment – Current Treatment: Physician Insights – Neuropathic Pain (US)
The treatment of neuropathic pain involves the use of drugs from several classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
Alopecia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary goal of treatment is…